Details

Autor(en) / Beteiligte

• Chasela, Charles S
• Hudgens, Michael G
• Jamieson, Denise J
• Kayira, Dumbani
• Hosseinipour, Mina C
• Kourtis, Athena P
• Martinson, Francis
• Tegha, Gerald
• Knight, Rodney J
• Ahmed, Yusuf I
• Kamwendo, Deborah D
• Hoffman, Irving F
• Ellington, Sascha R
• Kacheche, Zebrone
• Soko, Alice
• Wiener, Jeffrey B
• Fiscus, Susan A
• Kazembe, Peter
• Mofolo, Innocent A
• Chigwenembe, Maggie
• Sichali, Dorothy S
• van der Horst, Charles M

Titel

Maternal or Infant Antiretroviral Drugs to Reduce HIV-1 Transmission

Ist Teil von

• The New England journal of medicine, 2010-06, Vol.362 (24), p.2271-2281

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2010

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Approximately 200,000 infants worldwide become infected with human immunodeficiency virus type 1 (HIV-1) annually through breast-feeding. In this randomized trial involving 2369 mother–infant pairs in Malawi, the use of either maternal antiretroviral therapy or infant nevirapine through the age of 6 months was found to significantly decrease the rate of maternal transmission of HIV-1 during breast-feeding. Approximately 200,000 infants worldwide become infected annually with human immunodeficiency virus type 1 (HIV-1) through breast-feeding. 1 , 2 Without treatment, half of these infants will die before their second birthday. 3 Although formula feeding decreases the risk of postnatal HIV transmission, it is associated with an increased rate of early death. 4 , 5 Thus, exclusive breast-feeding is recommended by the World Health Organization (WHO) for infants of HIV-1–positive women for the first 6 months of life in resource-limited settings. 6 The use of antiretroviral drugs during pregnancy, labor, and delivery effectively reduces intrauterine and intrapartum HIV-1 transmission. 7 , 8 However, without prophylaxis, an additional 9% . . .